Active Surveillance for Prostate Cancer: Switch After 4 Years

Active surveillance instead of immediate aggressive treatment has become a standard of care for men with low-risk prostate cancer, and this initial management strategy has become increasing popular in recent years, show new data from a real-world study.   The study examined data on 17,000 men diagnosed with low-risk prostate cancer in Ontario, Canada between January 1, 2008 and December […]

Read more

Early ADT May Not Up OS in Prostate Cancer With PSA Relapse

Early initiation of continuous androgen-deprivation therapy (ADT) for prostate cancer patients who experience biochemical relapse may not meaningfully improve overall survival, according to new findings. A retrospective analysis with data from two institutions found that metastasis-free survival and overall survival were quite long among those who delayed hormone therapy. Among patients who experienced biochemical recurrence and whose prostate-specific antigen (PSA) […]

Read more

Androgen Blockers Likely Boost Survival in Older Men With Nonmetastatic CR Prostate Cancer

NEW YORK (Reuters Health) – Androgen receptor inhibitors improved survival in men ages 80 and older with non-metastatic, castration-resistant prostate cancer in a pooled analysis by the US Food and Drug Administration. “Older adults remain dismally underrepresented in most cancer clinical trials, due to a variety of factors, including restrictive eligibility criteria,” Dr. Jaleh Fallah of the FDA’s Center for […]

Read more

Guideline-Concordant Multimodality Care Tied to Fewer Deaths in High-Risk Prostate Cancer

NEW YORK (Reuters Health) – In high-risk prostate cancer patients with at least one additional adverse feature, guideline-concordant multimodal care was associated with greater prostate cancer-specific survival (PCSS) in a large retrospective study. Guideline-concordant multimodal treatment was defined as radical prostatectomy (RP) with appropriate use of multimodal therapy (optimal RP); external beam radiotherapy (EBRT) with at least two years of […]

Read more

Paving the Way for Diversity in Clinical Trials

“I’m the first person in my circle of family and friends to participate in a clinical trial.” Five years ago, Rhonda Long was diagnosed with cholangiocarcinoma, a rare bile duct cancer that’s seen in only about 8,000 Americans each year. At the time, Long, who is Black, said her doctor in Dayton, OH, told her she was not a candidate […]

Read more

These four symptoms indicate prostate cancer

What are the symptoms that indicate a change in the prostate? Prostate cancer is the most common cancer in men. Every year, around 60,000 new cases occur. According to information of the German cancer society every fourth Tumor in men develops in the prostate. Approximately 10 percent of the cases end fatally. Thus, the prostate cancer, together with lung and […]

Read more